Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
about
Effectiveness of second generation antipsychotics: a systematic review of randomized trialsPerphenazine for schizophreniaPharmacologic treatment of schizophreniaAntipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.Results of phase 3 of the CATIE schizophrenia trial.Extrapyramidal side-effects of antipsychotics in a randomised trial.Clinical and economic ramifications of switching antipsychotics in the treatment of schizophreniaEffectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsPredictors of switching antipsychotic medications in the treatment of schizophreniaSchizophrenia (maintenance treatment).World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.What CATIE found: results from the schizophrenia trial.Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trialAn update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand.Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database.Almost all antipsychotics result in weight gain: a meta-analysis.The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychoticsRandomized controlled trials for schizophrenia: study designs targeted to distinct goals.Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia.Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Managing weight in persons living with severe mental illness in community settings: a review of strategies used in community interventions.Clinical Practice Guidelines for Management of Schizophrenia.Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review.The SWITCH study: rationale and design of the trial.Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder.Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T.Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in JapanMethodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.Add-on oral olanzapine worsens hallucinations in schizoaffective disorder.Does early antipsychotic response predict long-term treatment outcome?Sensitivity of the Positive and Negative Syndrome Scale (PANSS) in Detecting Treatment Effects via Network Analysis.Response from the authors.Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
P2860
Q21260262-01553566-99D1-4D97-9D57-D3AF562E198EQ24187359-04269F55-15FF-477F-A2CD-76E47129F50AQ24604457-04B80335-F64F-4E11-8DBB-E01F216D009BQ30370326-CC3D584B-1D98-4FC9-9915-0242792017AEQ30487308-518DCA30-25CC-42AF-91FB-DC92228817BAQ30492645-7D04681B-5A5C-4D16-8EA0-6439F7EDD15CQ33499547-61F9313A-1F42-476A-AE1B-50D2A524920FQ33545458-D27B09F4-FA16-482A-88F3-B63D47E4DBA4Q33566124-026976B0-4FA3-4CD7-AD73-A9B968604A4CQ33709704-40C8F379-9B9A-4D57-BED8-B8C270E08D89Q34010697-C307A7FB-EE63-4EFC-A9E8-681262FD0DE6Q34315836-3AE1A412-AAAF-4A5E-9B8A-350A981ED855Q34413977-8ACE3278-EB2C-4DC5-9CA7-F56081D9C9BDQ34554423-55F0CD62-EC5E-430C-BD53-B0E207DD50D1Q34591378-3A32F4B4-E811-4049-8FD0-456FA3E5AE23Q34644655-7EC1E07B-EF79-48CD-886E-D44F208CEFB4Q34655500-71E90322-362C-4737-AF03-16EC7ECA99A7Q34659165-693E6FCD-35AD-487B-B1CB-904E787FCDACQ34661499-1D35CF82-5EEC-4650-AF61-A5CB5FD80107Q35370032-EF3DA140-A934-4F9A-9CD6-C958E3324555Q37075598-620BD325-274A-46A6-807F-675A722D088FQ37302639-528E6C3F-0672-4540-B5D7-8B4B91233D7CQ37310164-9EC16907-5BA1-4FAA-882F-78D7DA6044A4Q37425367-AAC5E484-BCEC-4C91-8B36-F54726AF40B3Q37546091-422C2D8D-0E2F-4094-B386-1F66DA79777BQ37623789-B9C2AECE-7BD0-4FE5-9CC7-82730B5B51C8Q37643030-EAA461B7-8C14-4825-ADEB-6EEBD9D4D3A8Q37725147-FAD23FD6-0BBB-4471-B393-E8B1B31584D5Q37999566-1BBFD636-EE06-4831-87AE-E6450A8C8EC8Q38201749-6CA2C601-3AFF-4207-BB6F-376443856655Q38979325-49FDBB48-AD24-4FA4-A4AF-DBB2A6630119Q39416493-9F906D9E-7033-4EBE-8526-E61CD5711B76Q40224374-01C44AED-6418-4FD1-8396-AC1AA49A72C5Q40427460-8C9E6F33-E34D-4FC4-AD64-FDCA6CC2AAD8Q41449760-0D5D5492-E6B1-43D5-9F12-BEEB82CD3F96Q42136122-4C95ADAA-88D9-4969-A21A-B16292E5F503Q48283069-A6FC8DB6-A2DD-4AF4-98AE-975AE2E0DDF3Q49852152-E80DE294-6EFE-46D5-9B51-C92FE56084DFQ50683127-5571C6EA-F6C3-42A5-8FF2-628843A8B4E2Q50683135-3E3126E5-2E0B-475C-BF77-384D6227A573
P2860
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@ast
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@en
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@nl
type
label
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@ast
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@en
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@nl
prefLabel
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@ast
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@en
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@nl
P2093
P1476
Effectiveness of olanzapine, q ...... g perphenazine: a CATIE study.
@en
P2093
Alexander L Miller
CATIE Investigators
George A Capuano
Irving Belz
John K Hsiao
Joseph P McEvoy
Marvin S Swartz
Richard S E Keefe
Sonia M Davis
T Scott Stroup
P304
P356
10.1176/AJP.2007.164.3.415
P407
P577
2007-03-01T00:00:00Z